Alpine Immune Sciences(US:ALPN)2022-05-12 20:25Financial Performance - The company reported a net loss of $7.5 million for the three months ended March 31, 2022, compared to a net loss of $10.6 million for the same period in 2021, indicating a reduction in losses year-over-year [62]. - The company reported a net loss of $7.5 million for the three months ended March 31, 2022, an improvement from a net loss of $10.6 million in the same period in 2021, reflecting a decrease of 29% [78]. - Collaboration revenue for the three months ended March 31, 2022, was $13.6 million, a significant increase from $3.2 million in the same period in 2021, representing a growth of approximately 326% [78]. - Revenue recognized from the AbbVie Agreement was $6 million for Q1 2022, compared to $3.2 million for Q1 2021 [66]. - Revenue recognized from the Horizon Agreement was $7.7 million for Q1 2022 [67]. - The company has not generated any product sales to date and does not expect to generate product revenue until successful development and commercialization of its product candidates [63]. Cash and Investments - As of March 31, 2022, the company had cash, cash equivalents, restricted cash, and investments totaling $219.1 million, which is crucial for funding ongoing operations and clinical trials [62]. - As of March 31, 2022, the company had cash and investments totaling $219.1 million, providing a solid liquidity position for ongoing operations [82]. - Net cash provided by operating activities was $5.4 million for the three months ended March 31, 2022, compared to a net cash used of $16.0 million in the same period in 2021 [87]. - The company received a $25.0 million upfront payment from Horizon as part of its collaboration agreement, contributing to the positive cash flow from operating activities [87]. - The company has outstanding principal of $7.0 million under its term loan agreement as of March 31, 2022, with obligations to meet certain covenants [84]. Research and Development - The company is aggressively advancing its lead autoimmune/inflammatory program, acazicolcept, through clinical development, including a Phase 2 study for systemic lupus erythematosus (SLE) [61]. - The company initiated a Phase 1 study of ALPN-303 in healthy volunteers in Q4 2021, with plans to move into clinical studies for B cell-mediated autoimmune/inflammatory diseases [61]. - The company is focused on developing davoceticept, a conditional CD28 costimulator, which has shown early evidence of clinical benefit in advanced malignancies [62]. - Research and development expenses totaled $16.3 million for Q1 2022, up from $10.4 million in Q1 2021, reflecting increased investment in product development [70]. - Direct research and development expenses by program totaled $9.1 million for Q1 2022, compared to $5.5 million for Q1 2021 [70]. - Research and development expenses increased by $5.9 million to $16.3 million, primarily due to a $3.8 million rise in clinical trial activities and $2.5 million in personnel-related expenses [80]. - The company expects to incur significant expenses and operating losses for at least the next several years as it continues to develop its product candidates and expand its pipeline [63]. - The company expects to continue incurring significant expenses and operating losses as it advances its research and clinical development efforts [91]. Collaborations and Partnerships - The company has entered into an exclusive license and collaboration agreement with Horizon Therapeutics, receiving an upfront payment of $25.0 million and an equity investment of $15.0 million, with potential future payments of up to $1.5 billion [60]. - AbbVie paid a nonrefundable upfront payment of $60 million and may pay up to $75 million upon achieving predefined development milestones [65]. - The company recognized no revenue from the Adaptimmune Agreement for Q1 2022, with potential future payments of up to $288 million based on milestone achievements [68]. - Collaboration revenue is expected to fluctuate quarterly, primarily derived from licensing agreements with AbbVie, Horizon, and Adaptimmune [64]. - Horizon made an upfront payment of $25 million and an equity investment of $15 million, with potential future payments of up to $1.5 billion based on success milestones [67]. Operational Expenses - General and administrative expenses are expected to increase as the company expands infrastructure and headcount [71]. - General and administrative expenses rose by $1.5 million to $4.8 million, driven by increases in personnel-related expenses and legal services [81]. - Interest expense primarily relates to a term loan with Silicon Valley Bank [72]. Future Outlook - The company anticipates continuing net losses and the need for potential equity or debt financing [94]. - Future capital requirements are uncertain and will depend on various factors, including the number of product candidates pursued and the costs of research and development [94]. - Available cash and cash equivalents are expected to fund operations for at least the next 12 months, based on current operating plans [94]. - The company may incur losses of up to approximately $1.8 million related to research and development credits subject to review by foreign taxing authorities [93]. - The company is exploring potential value-creating partnering opportunities to maximize the value of its pipeline and platform [62]. Lease and Facilities - The company entered into a lease for 27,164 square feet of office and laboratory space with an annual base rent of $1.7 million, increasing by 3.0% each year [92]. - A tenant improvement allowance of $5.4 million was received, with an additional maximum allowance of $1.8 million amortized over the lease term at an annual rate of 8.0% [92].